Darai E, Walker-Combrouze F, Fauconnier A, Madelenat P, Potet F, Scoazec J Y
Service de Gynécologie-Obstétrique, Hôpital Bichat-Claude Bernard, Paris, France.
Histopathology. 1998 Feb;32(2):151-9. doi: 10.1046/j.1365-2559.1998.00347.x.
To determine the diagnostic and prognostic value of the immunohistochemical analysis of CD44 variants in benign borderline and malignant tumours of the ovary.
The reactivity of tumour cells with three monoclonal antibodies, respectively, directed to all CD44 variants, CD44-v3 isoform and CD44-v6 isoform, was assessed by using an indirect immunoperoxidase technique applied to formalin-fixed, paraffin-embedded samples of 36 cases of borderline, as compared to 20 cases of benign tumours and 20 cases of carcinomas. CD44 variants were detected in 97% of borderline tumours, as compared to 60% of benign tumours and 100% of carcinomas. CD44-v3 was detected in 25% of borderline tumours, as compared to 0% of benign tumours (P = 0.003) and 55% of carcinomas (P = 0.065). The expression of CD44-v6 was detected in 28% of borderline tumours, as compared to 20% of benign tumours and 30% of carcinomas. In borderline tumours, as in carcinomas, CD44-v6, but not CD44-v3, expression was correlated with an increased proliferative index and with a higher incidence of p53 expression.
Borderline tumours of the ovary present frequent quantitative and qualitative alterations in the pattern of expression of CD44 proteins. However, these alterations are unlikely to represent useful diagnostic or prognostic markers.
确定CD44变体免疫组化分析在卵巢良性、交界性和恶性肿瘤中的诊断及预后价值。
采用间接免疫过氧化物酶技术，对36例交界性肿瘤、20例良性肿瘤和20例癌的福尔马林固定、石蜡包埋样本进行检测，评估肿瘤细胞与分别针对所有CD44变体、CD44-v3亚型和CD44-v6亚型的三种单克隆抗体的反应性。97%的交界性肿瘤检测到CD44变体，良性肿瘤为60%，癌为100%。25%的交界性肿瘤检测到CD44-v3，良性肿瘤为0%（P = 0.003），癌为55%（P = 0.065）。28%的交界性肿瘤检测到CD44-v6表达，良性肿瘤为20%，癌为30%。在交界性肿瘤中，与癌一样，CD44-v6而非CD44-v3的表达与增殖指数增加及p53表达发生率较高相关。
卵巢交界性肿瘤在CD44蛋白表达模式上存在频繁的定量和定性改变。然而，这些改变不太可能成为有用的诊断或预后标志物。
